Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care. Europe biodefense market reached $1,151.8 million in 2019 and will grow by 8.5% annually over 2020-2030 owing to the rising need for biodefense agents and equipment in the region. The rise in naturally occurring outbreaks, the threat posed by biological weapons, and the development of ICBMs with nuclear warheads are the main reasons why the biodefense market is expanding. Restrictive constraints, such as financial swings brought on by a changing EU, are anticipated to hinder market expansion in the years to come. The growth of biopharmaceuticals contract manufacturing is also anticipated to increase throughout the forecast period due to the rising implementation of technology and predictive analytics to redefine the biodefense market. The government spends a lot of money each year on vaccine research and development in order to be ready for potential bioterrorism threats. The UK government, for instance, published several documents in 2018: the Biological Security Strategy, Strategic Defense and Security Review, Global Health Security, UK Antimicrobial Resistance Strategy, National Counterterrorism Strategy, Counterterrorism Strategy CONTEST, National Counter-Proliferation Strategy to 2020, UK Influenza Preparedness Strategy, Strategy for UK Life Sciences, Vision, and High Level Strategy for UK Animal and Plant Health Research to 20. As the government engages in these current and future policy activities, understanding the existing biosecurity and biodefense policy, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for any bioterrorism. The initiatives of governments worldwide open a window of opportunities for the firms involved in the biodefense sector. Thus, owing to the factors mentioned above are likely to boost the growth of the Biodefense Market in Europe during the forecast period. Following the trends in the Asia-Pacific region the European market also gave the majority of the share to the Anthrax segment. This segment accounted for the largest market share in the Biodefense Market in Europe. The segment is expected to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives, such as BioWeapons Prevention Project (BWPP), British American Security Information Council (BASIC), and the German Biosecurity Programme.
The global struggle to tackle the COVID-19 pandemic has exposed the vulnerability of global societies to natural and manmade biological threats, prompting experts to warn of a potential increase in the use of biological weapons, like viruses or bacteria, in a post-coronavirus world. As a result of this the European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. All of these factors along with the plan to be prepared for the future has driven investors with large sum of money to the European Biodefence market, providing its further growth in the future
Highlighted with 35 tables and 41 figures, this 109-page report “Europe Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country.
By Product type
• Other Vaccines
• Biothreat Detection Devices
• Detectors/Triggering Devices
• Assays and Reagents
• Other Products
By Sales Channel
• Online Sales
• Offline Sales
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Achaogen, Inc., Alexeter Technologies LLC, Alnylam Pharmaceuticals, Inc., Altimmune, Inc., Bavarian Nordic AS, BioFactura, Inc., Cleveland Biolabs, Inc., Dynavax Technologies Inc, Dynport Vaccine Company LLC (DVC), Elusys Therapeutics, Inc., Emergent BioSolutions Inc, General Dynamics Corp., GlaxoSmithKline Plc, Ichor Medical Systems, Mediimmune (AstraZeneca), Nanotherapeutics, Inc., Ology Bioscience, PathSensors Inc, Pluristem Therapeutics, Sanofi Pasteur Ltd., SIGA Technologies, Inc., Soligenix, Inc., Xoma Corporation,
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globallyDownload Sample